ArticleFrontiers in medicine2025
Midaortic syndrome with IgA nephropathy in a child: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgA nephropathy (IgAN) is one of the most common glomerulonephritis characterized by deposition of IgA immune complex in the mesangial region and mesangial proliferation in children. It could progress to end stage renal disease. The underlying mechanism of IgAN is not fully understood. It has been known that IgAN could be secondary to autoimmune disorders, respiratory tract diseases, neoplasia, infection, gastrointestinal and liver diseases. Midaortic syndrome (MAS) is characterized by narrowing or occlusion of the distal thoracoabdominal aorta and the openings of its major branches, which may lead to organ damage like heart failure, renal dysfunction and even death. It may be congenital (present at birth) or acquired later in life. So far, no cases of IgAN concomitant with MAS have been reported. Case presentation: A 12-year-old boy was diagnosed with biopsy-proven IgAN, which was characterized by heavy proteinuria and hematuria. Additionally, MAS was found by performing abdominal computed tomography angiography (CTA) due to blood pressure difference between upper arm and thigh. Methylprednisolone and cyclophosphamide were used for treating IgAN. MAS was corrected with GORE-TEX Vascular Grafts (expanded polytetrafluoroethylene, ePTFE). Remission was achieved eventually. To the best of our knowledge, we are the first to report a childhood case who has IgAN concomitant with congenital MAS. We also presented a case-based review regarding the association between IgAN and vascular stenosis. Conclusion: MAS is an aggravating factor and might be a new cause of secondary IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.